SG11201804902UA - A composition for improving memory, learning ability, and cognitive ability - Google Patents

A composition for improving memory, learning ability, and cognitive ability

Info

Publication number
SG11201804902UA
SG11201804902UA SG11201804902UA SG11201804902UA SG11201804902UA SG 11201804902U A SG11201804902U A SG 11201804902UA SG 11201804902U A SG11201804902U A SG 11201804902UA SG 11201804902U A SG11201804902U A SG 11201804902UA SG 11201804902U A SG11201804902U A SG 11201804902UA
Authority
SG
Singapore
Prior art keywords
ability
peptide
composition
improving memory
learning
Prior art date
Application number
SG11201804902UA
Inventor
Yongkoo Kang
Original Assignee
Brainon Inc
Yongkoo Kang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150183011A external-priority patent/KR101706296B1/en
Priority claimed from KR1020160026600A external-priority patent/KR101844481B1/en
Application filed by Brainon Inc, Yongkoo Kang filed Critical Brainon Inc
Publication of SG11201804902UA publication Critical patent/SG11201804902UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Psychology (AREA)

Abstract

ACOMPOSITION FOR IMPROVING MEMORY, LEARNING ABILITY, AND COGNITIVE ABILITY [] There is provided a composition for improving memory, learning ability, and cognitive ability. It has been confirmed that a peptide having a C-terminal region ended to GAG had an effect of improving the memory. In order for the peptide to have the effect, it has been confirmed that the peptide should be a peptide of which the length consists of at least amino acids. Further, it has been confirmed that a peptide of which the length of the peptide having the C-terminal region ended to GAG consists of 5 to 9 amino acids has the same effect. As a result, the peptide of the present invention can be used as the composition for improving memory, learning ability, and cognitive ability. (Figure: NIL) -20-
SG11201804902UA 2015-12-21 2016-05-03 A composition for improving memory, learning ability, and cognitive ability SG11201804902UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150183011A KR101706296B1 (en) 2015-12-21 2015-12-21 A composition for memory, cognition, or learning abilities
KR1020160026600A KR101844481B1 (en) 2016-03-04 2016-03-04 A Peptides for improving memory
PCT/KR2016/004650 WO2017111215A1 (en) 2015-12-21 2016-05-03 Composition for improving memory, learning ability and cognition

Publications (1)

Publication Number Publication Date
SG11201804902UA true SG11201804902UA (en) 2018-07-30

Family

ID=59090692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804902UA SG11201804902UA (en) 2015-12-21 2016-05-03 A composition for improving memory, learning ability, and cognitive ability

Country Status (14)

Country Link
US (4) US20180201645A1 (en)
EP (1) EP3255055B1 (en)
JP (1) JP6463499B2 (en)
CN (2) CN110279845B (en)
AU (2) AU2016376059B2 (en)
CA (1) CA2965840C (en)
MX (1) MX2018006823A (en)
MY (1) MY197348A (en)
PH (1) PH12017550079A1 (en)
RU (1) RU2694064C1 (en)
SA (1) SA518391710B1 (en)
SG (1) SG11201804902UA (en)
TR (1) TR201807610T1 (en)
WO (1) WO2017111215A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743293C1 (en) * 2020-07-06 2021-02-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Use of Gly-His-Lys-Val-Glu-Pro peptide to improve learning abilty and memory.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243038A (en) * 1986-11-04 1993-09-07 Protein Polymer Technologies, Inc. Construction of synthetic DNA and its use in large polypeptide synthesis
AU612340B2 (en) 1986-11-04 1991-07-11 Protein Polymers Technologies, Inc. Construction of synthetic dna and its use in large polypeptide synthesis
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
US6069129A (en) * 1998-03-13 2000-05-30 Mrs, Llc Elastin derived composition and method of using same
EP1104304A1 (en) * 1998-08-13 2001-06-06 G.D. Searle & Co. Multivalent avb3 and metastasis-associated receptor ligands
US6608242B1 (en) 2000-05-25 2003-08-19 E. I. Du Pont De Nemours And Company Production of silk-like proteins in plants
AU2001282437A1 (en) * 2000-07-31 2002-02-13 Amidut Ltd. Detecting anti-viral drug candidates and resistance
EA007792B1 (en) * 2001-02-22 2007-02-27 Зеаланд Фарма А/С Medical uses of intercellular communication facilitating compounds
US7056889B2 (en) * 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
CN1532281A (en) * 2003-03-21 2004-09-29 吉林大学第一医院 Recombination of Carcinoembryonic Antigen Gene Fragment and Gene Vaccine
JP4629046B2 (en) * 2003-05-14 2011-02-09 ダニスコ・ユーエス・インコーポレーテッド Repeat sequence protein polymer active agent conjugates, methods and uses
US7148192B2 (en) 2004-01-29 2006-12-12 Ebwe Pharma Ges. M.H. Nfg.Kg Neuroprotective dietary supplement
KR20050082389A (en) * 2004-02-18 2005-08-23 메덱스젠 주식회사 Pharmaceutical composition for treatment of transplantation rejection comprising concatameric immunoadhesin
KR100494358B1 (en) * 2004-07-30 2005-06-10 주식회사 바이오그랜드 Compositions for Improving Brain or Cognitive Function
KR20070000892A (en) * 2005-06-28 2007-01-03 하성원 How to Play Silkworm Silk Fibroin
BRPI0614419A2 (en) * 2005-08-16 2011-03-29 Copenhagen University gdnf-derived peptides
AU2006310882A1 (en) * 2005-11-07 2007-05-10 Copenhagen University Neurotrophin-derived peptide sequences
US20090306009A1 (en) * 2005-12-06 2009-12-10 P2-Science Aps Modulation of the P2Y2 Receptor Pathway
WO2007124593A1 (en) * 2006-05-02 2007-11-08 Universite Laval Branched peptide amplification and uses thereof
KR100864380B1 (en) * 2006-10-17 2008-10-21 주식회사 브레인가드 Peptides for improving brain function and preventing or treating cerebral nervous system diseases
WO2010054319A2 (en) * 2008-11-10 2010-05-14 Codexis, Inc. Penicillin-g acylases
JP2013503634A (en) * 2009-09-02 2013-02-04 カンザス ステイト ユニバーシティ リサーチ ファウンデーション Protease MRI and optical assays
US8916679B2 (en) * 2009-12-01 2014-12-23 Universita′ degli Studi di Modena e Reggio Emilia Peptides binding to the dimer interface of thymidylate synthase for the treatment of cancer
WO2011119484A1 (en) * 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
SG186068A1 (en) 2010-05-27 2013-01-30 Janssen Biotech Inc Insulin-like growth factor 1 receptor binding peptides
JP2012017287A (en) * 2010-07-07 2012-01-26 Iwate Univ Therapeutic agent for senile disease
WO2012092718A1 (en) * 2011-01-07 2012-07-12 Nanjing University Photo-responsive supramolecular hydrogels
US9506932B2 (en) * 2011-04-21 2016-11-29 Biomerieux, Inc. Method of detecting at least one mechanism of resistance to cephalosporins by mass spectrometry
CN105229024A (en) * 2013-03-15 2016-01-06 Uab研究基金会 The methods for the treatment of of nephrotic syndrome and related pathologies
KR20150114916A (en) * 2014-04-02 2015-10-13 조아제약주식회사 Composition for Enhancing Memory or Improving concentration
KR101430387B1 (en) * 2014-04-08 2014-08-13 강용구 Peptides derived from silk fibroin and composition for memory, cognition, or learning abilities or dementia comprising the same

Also Published As

Publication number Publication date
CA2965840C (en) 2021-11-30
TR201807610T1 (en) 2018-06-21
SA518391710B1 (en) 2022-11-09
CN107406482A (en) 2017-11-28
CN110279845B (en) 2021-08-20
AU2016376059B2 (en) 2019-02-14
MY197348A (en) 2023-06-14
AU2016376059A1 (en) 2017-10-05
US10435436B2 (en) 2019-10-08
PH12017550079A1 (en) 2018-02-12
EP3255055A4 (en) 2018-04-18
AU2019200449A1 (en) 2019-02-07
RU2694064C1 (en) 2019-07-09
CN110279845A (en) 2019-09-27
CA2965840A1 (en) 2017-06-29
JP6463499B2 (en) 2019-02-06
US20220296673A1 (en) 2022-09-22
EP3255055A1 (en) 2017-12-13
WO2017111215A1 (en) 2017-06-29
BR112018012527A2 (en) 2018-12-11
US20180327452A1 (en) 2018-11-15
EP3255055B1 (en) 2024-06-05
JP2018517394A (en) 2018-07-05
US20180201645A1 (en) 2018-07-19
US20180327451A1 (en) 2018-11-15
EP3255055C0 (en) 2024-06-05
MX2018006823A (en) 2018-11-29

Similar Documents

Publication Publication Date Title
PH12019502279A1 (en) Cleaning compositions and uses thereof
SA519402400B1 (en) Compositions and methods for the treatment of hemoglobinopathies
PH12018501355A1 (en) Rsv f protein mutants
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
MX2017009595A (en) Anti-senescence compounds and uses thereof.
MX389228B (en) Compositions for treating the hair
SG10201810124PA (en) Improved immunoglobulin variable domains
PH12016501441A1 (en) Chimeric alkaline phosphate-like proteins
PH12018502714A1 (en) Nicotine particles and compositions
MY182177A (en) Method for masking bitterness of composition containing collagen peptide
EA201890815A1 (en) AMINO ACID COMPOSITIONS WITH MODIFIED DELIVERY FOR ORAL ADMINISTRATION
MX2016011745A (en) Hppd variants and methods of use.
MX2017008908A (en) Process for the hydrolysis of keratin employing proteases.
JOP20200323A1 (en) Methods of manufacturing amino acid compositions
SG10201805039UA (en) Protease resistant peptides
MX2018014966A (en) Protease-resistant mono-lipidated peptides.
MX2015002279A (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.
BR112016023519A2 (en) wnt / ß-catenin signaling inhibitor, pharmaceutical composition and method of treating and / or preventing a pathology defined by vascular malformation
PH12017502323B1 (en) Novel xylanase
NZ744289A (en) Composition containing amino acids
SG11201804902UA (en) A composition for improving memory, learning ability, and cognitive ability
MX365952B (en) Compositions for preventing and/or treating pathological conditions associated with alpha-glucosidase.
MX2018009676A (en) Process.
MX383947B (en) Collagen 7 compositions and methods of using the same
WO2018203737A3 (en) Method for extending half-life of protein